CN114042143A - 一种护肝解酒藏药组方的制备方法 - Google Patents
一种护肝解酒藏药组方的制备方法 Download PDFInfo
- Publication number
- CN114042143A CN114042143A CN202111351160.7A CN202111351160A CN114042143A CN 114042143 A CN114042143 A CN 114042143A CN 202111351160 A CN202111351160 A CN 202111351160A CN 114042143 A CN114042143 A CN 114042143A
- Authority
- CN
- China
- Prior art keywords
- parts
- tibetan
- liver
- tibetan medicine
- particle size
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 45
- 230000000694 effects Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 210000004185 liver Anatomy 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 241000222336 Ganoderma Species 0.000 claims abstract description 19
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 19
- 235000008397 ginger Nutrition 0.000 claims abstract description 19
- 206010004542 Bezoar Diseases 0.000 claims abstract description 11
- 235000002566 Capsicum Nutrition 0.000 claims abstract description 11
- 235000002787 Coriandrum sativum Nutrition 0.000 claims abstract description 11
- 244000124209 Crocus sativus Species 0.000 claims abstract description 11
- 235000015655 Crocus sativus Nutrition 0.000 claims abstract description 11
- 239000006002 Pepper Substances 0.000 claims abstract description 11
- 235000016761 Piper aduncum Nutrition 0.000 claims abstract description 11
- 235000017804 Piper guineense Nutrition 0.000 claims abstract description 11
- 235000008184 Piper nigrum Nutrition 0.000 claims abstract description 11
- 244000042430 Rhodiola rosea Species 0.000 claims abstract description 11
- 235000003713 Rhodiola rosea Nutrition 0.000 claims abstract description 11
- 235000013974 saffron Nutrition 0.000 claims abstract description 11
- 239000004248 saffron Substances 0.000 claims abstract description 11
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910052602 gypsum Inorganic materials 0.000 claims abstract description 8
- 239000010440 gypsum Substances 0.000 claims abstract description 8
- 240000002943 Elettaria cardamomum Species 0.000 claims abstract description 5
- 235000005300 cardamomo Nutrition 0.000 claims abstract description 5
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 5
- 244000273928 Zingiber officinale Species 0.000 claims abstract 5
- 244000018436 Coriandrum sativum Species 0.000 claims abstract 4
- 244000203593 Piper nigrum Species 0.000 claims abstract 4
- 238000002156 mixing Methods 0.000 claims description 55
- 239000000284 extract Substances 0.000 claims description 47
- 239000002245 particle Substances 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- 238000010298 pulverizing process Methods 0.000 claims description 40
- 230000001954 sterilising effect Effects 0.000 claims description 40
- 238000001704 evaporation Methods 0.000 claims description 39
- 239000007788 liquid Substances 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 24
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 22
- 229930195725 Mannitol Natural products 0.000 claims description 22
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 22
- 229930006000 Sucrose Natural products 0.000 claims description 22
- 239000000594 mannitol Substances 0.000 claims description 22
- 235000010355 mannitol Nutrition 0.000 claims description 22
- 239000005720 sucrose Substances 0.000 claims description 22
- 206010019133 Hangover Diseases 0.000 claims description 20
- 239000007910 chewable tablet Substances 0.000 claims description 20
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- -1 decoction Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 8
- 230000001376 precipitating effect Effects 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 8
- 235000001892 vitamin D2 Nutrition 0.000 claims description 8
- 239000011653 vitamin D2 Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 244000059800 Amomum compactum Species 0.000 claims description 6
- 235000016426 Amomum compactum Nutrition 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 4
- 229910021532 Calcite Inorganic materials 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000002994 raw material Substances 0.000 claims 2
- 238000002390 rotary evaporation Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 8
- 206010047700 Vomiting Diseases 0.000 abstract description 6
- 230000008673 vomiting Effects 0.000 abstract description 5
- 230000036528 appetite Effects 0.000 abstract description 3
- 235000019789 appetite Nutrition 0.000 abstract description 3
- 208000002173 dizziness Diseases 0.000 abstract description 3
- 230000035622 drinking Effects 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 206010019233 Headaches Diseases 0.000 abstract description 2
- 230000002496 gastric effect Effects 0.000 abstract description 2
- 231100000869 headache Toxicity 0.000 abstract description 2
- 230000004044 response Effects 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 abstract description 2
- 238000010792 warming Methods 0.000 abstract description 2
- 208000004880 Polyuria Diseases 0.000 abstract 1
- 230000035619 diuresis Effects 0.000 abstract 1
- 210000000232 gallbladder Anatomy 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 35
- 241000234314 Zingiber Species 0.000 description 14
- 229940068682 chewable tablet Drugs 0.000 description 13
- 239000000463 material Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 241000208308 Coriandrum Species 0.000 description 7
- 241000722363 Piper Species 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000005336 cracking Methods 0.000 description 5
- 230000001476 alcoholic effect Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/413—Gall bladder; Bile
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Manufacturing & Machinery (AREA)
Abstract
本发明公开了一种护肝解酒藏药组方及其制备方法,属于藏药技术领域。本发明是由下述质量份的藏药组成:藏红花1~3份、藏木香4~6份、干姜9~12份、芫荽9~12份、牛黄10~15份,豆蔻3~5份,胡椒0.2~0.6份,红景天0.8~1.2份,寒水石20~30份,灵芝40~60份。本发明具有开窍醒神、温中和气、疏肝利胆、健脾开胃、终呕止吐、解毒利尿等功效,对缓解酒后恶心呕吐、头晕头痛、胃脘胀满、不思饮食等具有良好效果,能够解酒护肝,清胃排毒。本发明疗效可靠,服用方便,见效快速,安全无毒副作用。
Description
技术领域
本发明涉及藏药技术领域,具体涉及一种护肝解酒藏药组方的制备方法。
背景技术
随着人们生活水平的不断提高,高蛋白高脂肪食品的摄入已成常态,人们相聚饮酒取乐也成为一种社交习惯。但过量饮酒会导致头晕脑胀、恶心呕吐、身体失衡、语无伦次等一系列副作用,不仅对身体造成伤害,也严重影响正常的生活、学习和工作。长期过量饮酒可能会导致酒精肝、脂肪肝、肝硬化等疾病,也会引发慢性胰腺炎、肠胃炎、胃溃疡等疾病。因此,研发具有护肝解酒功效的药品或保健品,减轻酒精对饮酒者的伤害,具有重要的现实意义和社会意义。目前市场上护肝解酒药品较多,但效果不是太好,长期服用可能还对身体有副作用。
中医药治疗酒精肝有着悠久的历史,在治疗用药方面积累了丰富的经验,有广阔的开发前景和独特的优势。
发明内容
本发明的目的是针对现有护肝解酒组方存在的问题,提供一种无毒无副作用的护肝解酒组方的制备方法。
本发明采用的技术方案如下:
一种护肝解酒藏药组方,由下述质量份的藏药组成:藏红花1~3份、藏木香4~6份、干姜9~12份、芫荽9~12份、牛黄10~15份,豆蔻3~5份,胡椒0.2~0.6份,红景天0.8~1.2份,寒水石20~30份,灵芝40~60份。优选地,一种护肝解酒藏药组方,由下述质量份的藏药组成:藏红花2份、藏木香5份、干姜10份、芫荽11份、牛黄13份,豆蔻4份,胡椒0.5份,红景天1.1份,寒水石28份,灵芝55份。
上述护肝解酒藏药组方,可制备成固体制剂或液体制剂,比如散剂、丸剂、颗粒剂、汤剂、片剂、胶囊、口服液、煎膏剂、糖浆剂、合剂、咀嚼片或茶饮。优选地制成咀嚼片。
藏药有效成分的提取是制剂的关键步骤,在提取过程中,提取工艺参数是影响提取效果的关键因素,因此,选用合理的提取参数能够提高药材有效成分的提取率,从而使制剂达到较好的药用效果。
上述护肝解酒藏药组方制备成制剂的的制备方法,包括以下步骤:
1.取藏红花进行纳米粉碎至粒径小于100nm,灭菌,备用。
2.取藏木香,加水微波提取两次,每次40min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
3.取干姜,加水微波提取两次,每次30min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
4.取芫荽进行纳米粉碎至粒径小于100nm,灭菌,备用。
5.取牛黄进行纳米粉碎至粒径小于100nm,灭菌,备用。
6.取豆蔻加水微波提取三次,每次50min,料液比1:12。合并提取液,旋转蒸发浓缩为浸膏状。
7.取胡椒进行纳米粉碎至粒径小于100nm,灭菌,备用。
8.取红景天进行纳米粉碎至粒径小于100nm,灭菌,备用。
9.取寒水石加水微波提取三次,每次50min,料液比1:12。合并提取液,旋转蒸发至1/3体积,加三倍无水乙醇进行醇沉,抽滤除去沉淀,再旋转浓缩为浸膏状。
10.取灵芝加水微波提取两次,每次30min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
将用上述提取方法得到的中间体混合,加入制备相关辅料,制成制剂即可。
一种上述护肝解酒藏药组方咀嚼片的制备方法,包括以下操作步骤:
1.取藏红花进行纳米粉碎至粒径小于100nm,灭菌,备用。
2.取藏木香,加水微波提取两次,每次40min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
3.取干姜,加水微波提取两次,每次30min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
4.取芫荽进行纳米粉碎至粒径小于100nm,灭菌,备用。
5.取牛黄进行纳米粉碎至粒径小于100nm,灭菌,备用。
6.取豆蔻加水微波提取三次,每次50min,料液比1:12。合并提取液,旋转蒸发浓缩为浸膏状。
7.取胡椒进行纳米粉碎至粒径小于100nm,灭菌,备用。
8.取红景天进行纳米粉碎至粒径小于100nm,灭菌,备用。
9.取寒水石加水微波提取三次,每次50min,料液比1:12。合并提取液,旋转蒸发至1/3体积,加三倍无水乙醇进行醇沉,抽滤除去沉淀,再旋转浓缩为浸膏状。
10.取灵芝加水微波提取两次,每次30min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
11.取蔗糖、甘露醇进行纳米粉碎至粒径小于100nm,备用;
11.取步骤2、3、6、9、10的浸膏,加入步骤1、4、5、7、8、11的粉末,混合,制粒,干燥,整粒,再加入2%的硬脂酸镁,混匀整粒,压片,即得成品。
上述护肝解酒藏药组方咀嚼片的制备方法,所述蔗糖和甘露醇粉末的加入量的重量百分比为20%~40%;所述蔗糖和甘露醇粉末的重量比为3:1~1:1。
本发明的藏药组方所用配方配伍合理严谨,提取方法科学,具有益气升阳、醒神开窍、温中和气、解毒利尿、清胃止呕、护肝解酒之功效,产品易于携带,服用方便,安全可靠,无毒副作用,而且成本低廉,生产工艺简单。
具体实施方式
下面结合具体实施例对本发明作进一步描述,但不限制本发明的保护范围和应用范围。
一、护肝解酒藏药组方咀嚼片的制备
实施例1
一种护肝解酒藏药组方咀嚼片的制备方法,包括以下操作步骤:
1.按照以下重量称取藏药组分:藏红花2kg、藏木香5kg、干姜10kg、芫荽11kg、牛黄13kg,豆蔻4kg,胡椒0.5kg,红景天1.1kg,寒水石28kg,灵芝55kg。
2.取藏红花进行纳米粉碎至粒径小于100nm,灭菌,备用。
3.取藏木香,加水微波提取两次,每次40min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
4.取干姜,加水微波提取两次,每次30min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
5.取芫荽进行纳米粉碎至粒径小于100nm,灭菌,备用。
6.取牛黄进行纳米粉碎至粒径小于100nm,灭菌,备用。
7.取豆蔻加水微波提取三次,每次50min,料液比1:12。合并提取液,旋转蒸发浓缩为浸膏状。
8.取胡椒进行纳米粉碎至粒径小于100nm,灭菌,备用。
9.取红景天进行纳米粉碎至粒径小于100nm,灭菌,备用。
10.取寒水石加水微波提取三次,每次50min,料液比1:12。合并提取液,旋转蒸发至1/3体积,加三倍无水乙醇进行醇沉,抽滤除去沉淀,再旋转浓缩为浸膏状。
11.取灵芝加水微波提取两次,每次30min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
12.取蔗糖、甘露醇进行纳米粉碎至粒径小于100nm,备用;
13.取步骤3、4、7、10、11的浸膏,加入步骤2、5、6、8、9、12的粉末(蔗糖和甘露醇粉末的加入量的重量百分比为30%;所述蔗糖和甘露醇粉末的重量比为2:1),混合,制粒,干燥,整粒,再加入2%的硬脂酸镁,混匀整粒,压片,即得成品。
制备所得咀嚼片完整均匀,表面光滑,色泽光洁,无裂片及粘冲现象,气味清凉,口味清香,略甜,可口。
实施例2
一种护肝解酒藏药组方咀嚼片的制备方法,包括以下操作步骤:
1.按照以下重量称取藏药组分:藏红花1kg、藏木香4kg、干姜9kg、芫荽9kg、牛黄10kg,豆蔻3kg,胡椒0.2kg,红景天0.8kg,寒水石20kg,灵芝40kg。
2.取藏红花进行纳米粉碎至粒径小于100nm,灭菌,备用。
3.取藏木香,加水微波提取两次,每次40min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
4.取干姜,加水微波提取两次,每次30min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
5.取芫荽进行纳米粉碎至粒径小于100nm,灭菌,备用。
6.取牛黄进行纳米粉碎至粒径小于100nm,灭菌,备用。
7.取豆蔻加水微波提取三次,每次50min,料液比1:12。合并提取液,旋转蒸发浓缩为浸膏状。
8.取胡椒进行纳米粉碎至粒径小于100nm,灭菌,备用。
9.取红景天进行纳米粉碎至粒径小于100nm,灭菌,备用。
10.取寒水石加水微波提取三次,每次50min,料液比1:12。合并提取液,旋转蒸发至1/3体积,加三倍无水乙醇进行醇沉,抽滤除去沉淀,再旋转浓缩为浸膏状。
11.取灵芝加水微波提取两次,每次30min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
12.取蔗糖、甘露醇进行纳米粉碎至粒径小于100nm,备用;
13.取步骤3、4、7、10、11的浸膏,加入步骤2、5、6、8、9、12的粉末(蔗糖和甘露醇粉末的加入量的重量百分比为20%;所述蔗糖和甘露醇粉末的重量比为1:1),混合,制粒,干燥,整粒,再加入2%的硬脂酸镁,混匀整粒,压片,即得成品。
制备所得咀嚼片完整均匀,表面光滑,色泽光洁,无裂片及粘冲现象,气味清凉,口味清香,略甜,可口。
实施例3
一种护肝解酒藏药组方咀嚼片的制备方法,包括以下操作步骤:
1.按照以下重量称取藏药组分:藏红花3kg、藏木香6kg、干姜12kg、芫荽12kg、牛黄15kg,豆蔻5kg,胡椒0.6kg,红景天1.2kg,寒水石30kg,灵芝60kg。
2.取藏红花进行纳米粉碎至粒径小于100nm,灭菌,备用。
3.取藏木香,加水微波提取两次,每次40min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
4.取干姜,加水微波提取两次,每次30min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
5.取芫荽进行纳米粉碎至粒径小于100nm,灭菌,备用。
6.取牛黄进行纳米粉碎至粒径小于100nm,灭菌,备用。
7.取豆蔻加水微波提取三次,每次50min,料液比1:12。合并提取液,旋转蒸发浓缩为浸膏状。
8.取胡椒进行纳米粉碎至粒径小于100nm,灭菌,备用。
9.取红景天进行纳米粉碎至粒径小于100nm,灭菌,备用。
10.取寒水石加水微波提取三次,每次50min,料液比1:12。合并提取液,旋转蒸发至1/3体积,加三倍无水乙醇进行醇沉,抽滤除去沉淀,再旋转浓缩为浸膏状。
11.取灵芝加水微波提取两次,每次30min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
12.取蔗糖、甘露醇进行纳米粉碎至粒径小于100nm,备用;
13.取步骤3、4、7、10、11的浸膏,加入步骤2、5、6、8、9、12的粉末(蔗糖和甘露醇粉末的加入量的重量百分比为40%;所述蔗糖和甘露醇粉末的重量比为3:1),混合,制粒,干燥,整粒,再加入2%的硬脂酸镁,混匀整粒,压片,即得成品。
制备所得咀嚼片完整均匀,表面光滑,色泽光洁,无裂片及粘冲现象,气味清凉,口味清香,略甜,可口。
实施例4
一种护肝解酒藏药组方咀嚼片的制备方法,包括以下操作步骤:
1.按照以下重量称取藏药组分:藏红花2kg、藏木香6kg、干姜9kg、芫荽11kg、牛黄14kg,豆蔻5kg,胡椒0.3kg,红景天0.9kg,寒水石22kg,灵芝43kg。
2.取藏红花进行纳米粉碎至粒径小于100nm,灭菌,备用。
3.取藏木香,加水微波提取两次,每次40min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
4.取干姜,加水微波提取两次,每次30min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
5.取芫荽进行纳米粉碎至粒径小于100nm,灭菌,备用。
6.取牛黄进行纳米粉碎至粒径小于100nm,灭菌,备用。
7.取豆蔻加水微波提取三次,每次50min,料液比1:12。合并提取液,旋转蒸发浓缩为浸膏状。
8.取胡椒进行纳米粉碎至粒径小于100nm,灭菌,备用。
9.取红景天进行纳米粉碎至粒径小于100nm,灭菌,备用。
10.取寒水石加水微波提取三次,每次50min,料液比1:12。合并提取液,旋转蒸发至1/3体积,加三倍无水乙醇进行醇沉,抽滤除去沉淀,再旋转浓缩为浸膏状。
11.取灵芝加水微波提取两次,每次30min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
12.取蔗糖、甘露醇进行纳米粉碎至粒径小于100nm,备用;
13.取步骤3、4、7、10、11的浸膏,加入步骤2、5、6、8、9、12的粉末(蔗糖和甘露醇粉末的加入量的重量百分比为25%;所述蔗糖和甘露醇粉末的重量比为2:1),混合,制粒,干燥,整粒,再加入2%的硬脂酸镁,混匀整粒,压片,即得成品。
制备所得咀嚼片完整均匀,表面光滑,色泽光洁,无裂片及粘冲现象,气味清凉,口味清香,略甜,可口。
实施例5
一种护肝解酒藏药组方咀嚼片的制备方法,包括以下操作步骤:
1.按照以下重量称取藏药组分:藏红花1kg、藏木香5kg、干姜10kg、芫荽11kg、牛黄11kg,豆蔻3kg,胡椒0.5kg,红景天1.2kg,寒水石26kg,灵芝55kg。
2.取藏红花进行纳米粉碎至粒径小于100nm,灭菌,备用。
3.取藏木香,加水微波提取两次,每次40min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
4.取干姜,加水微波提取两次,每次30min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
5.取芫荽进行纳米粉碎至粒径小于100nm,灭菌,备用。
6.取牛黄进行纳米粉碎至粒径小于100nm,灭菌,备用。
7.取豆蔻加水微波提取三次,每次50min,料液比1:12。合并提取液,旋转蒸发浓缩为浸膏状。
8.取胡椒进行纳米粉碎至粒径小于100nm,灭菌,备用。
9.取红景天进行纳米粉碎至粒径小于100nm,灭菌,备用。
10.取寒水石加水微波提取三次,每次50min,料液比1:12。合并提取液,旋转蒸发至1/3体积,加三倍无水乙醇进行醇沉,抽滤除去沉淀,再旋转浓缩为浸膏状。
11.取灵芝加水微波提取两次,每次30min,料液比1:10。合并提取液,旋转蒸发浓缩为浸膏状。
12.取蔗糖、甘露醇进行纳米粉碎至粒径小于100nm,备用;
13.取步骤3、4、7、10、11的浸膏,加入步骤2、5、6、8、9、12的粉末(蔗糖和甘露醇粉末的加入量的重量百分比为35%;所述蔗糖和甘露醇粉末的重量比为3:1),混合,制粒,干燥,整粒,再加入2%的硬脂酸镁,混匀整粒,压片,即得成品。
制备所得咀嚼片完整均匀,表面光滑,色泽光洁,无裂片及粘冲现象,气味清凉,口味清香,略甜,可口。
二、药效学实验
1.实验材料:上述制备好的实施例1-4样品;酒精,选用52°的世纪金徽白酒。
2.动物:健康小鼠60只,雄性,7-8周龄,体重30±3g,普通饲料饲喂,自由进水进食。
3.动物分组:随机将小鼠分为6组(每组10只),即分为空白对照组、模型对照组、实施例1、实施例2、实施例3、实施例4.
空白组饲喂生理盐水;模型组饲喂52°的世纪金徽白酒(1.5g/kg);实施例1-4组先分别饲喂实施例1-4样品(8g/kg),1.5h后再饲喂52°的世纪金徽白酒(1.5g/kg)。
4.检测方法:喂养30天后,摘取眼球取血,分离血清并低温保存,待检测。
5.实验结果:
(1)生长状况:空白对照组小鼠毛发顺滑,有光泽,行动活泼,体态灵敏,进食量及排便均正常,体重平均约增加6g。模型对照组小鼠毛发光泽度较差,行动迟缓,体态灵敏度差,进食量减少,排便稀溏,体重平均约增加2g。实施例1-4组小鼠毛发基本光泽,行动较活泼,体态较灵敏,进食量及排便基本正常,体重平均约增加4g。
(2)血清ALT、AST、GGT比较:具体见下表,空白对照组的血清ALT、AST、GGT显著低于模型对照组和实施例1-4组(p<0.05);和模型对照组相比,实施例组能显著降低血清ALT、AST、GGT水平(p<0.05)。
各组血清ALT、AST、GGT(x±s,n=10,U/L)
组别 | ALT | AST | GGT |
空白对照组 | 7.54±0.80a | 8.90±0.93a | 16.27±0.83a |
模型对照组 | 40.05±1.36d | 38.58±1.09e | 36.24±0.87d |
实施例1组 | 24.71±0.85b | 22.18±1.28d | 28.64±0.92c |
实施例2组 | 25.08±0.82b | 20.67±0.89c | 27.95±1.09c |
实施例3组 | 28.08±0.88c | 18.93±0.93b | 25.67±1.62b |
实施例4组 | 27.73±0.98c | 21.19±1.03c | 26.15±1.49b |
6.结论:ALT、AST、GGT是肝细胞破坏后所释放出来的酶,本实验通过测定不同处理组小鼠血清中ALT、AST、GGT的水平,来推测小鼠肝脏系统的炎症或病变坏死情况。结果表明,本发明能有效降低饲喂酒精的小鼠血清中ALT、AST、GGT的水平,增强小鼠活动能力,表明本发明能改善酒精对肝脏产生的不利影响,对酒精性肝损伤有保护作用。
三、临床应用
本发明护肝解酒藏药组方,在藏族群众中广泛用于养肝护肝及解酒使用。将上述实施例2制备好的咀嚼片给80例饮酒者服用(用法:嚼服,每次2片,饮酒前或饮酒后服用均可),进行了为期一年的观察,并记录了临床效果。结果表明,服用后对缓解酒后恶心呕吐、头晕头痛、胃脘胀满、不思饮食等具有良好效果,疗效可靠,服用方便,见效快速,安全无毒副作用。
Claims (7)
1.一种护肝解酒藏药组方,其特征在于,按重量份数计,原料包括:藏红花1~3份、藏木香4~6份、干姜9~12份、芫荽9~12份、牛黄10~15份,豆蔻3~5份,胡椒0.2~0.6份,红景天0.8~1.2份,寒水石20~30份,灵芝40~60份。
2.根据权利要求1所述一种护肝解酒藏药组方,其特征在于,按重量份数计,原料包括:藏红花2份、藏木香5份、干姜10份、芫荽11份、牛黄13份,豆蔻4份,胡椒0.5份,红景天1.1份,寒水石28份,灵芝55份。
3.根据权利要求2所述一种护肝解酒藏药组方,其特征在于:所述藏药组方制成散剂、丸剂、颗粒剂、汤剂、片剂、胶囊、口服液、煎膏剂、糖浆剂、合剂、咀嚼片或茶饮。
4.一种根据权利要求1-3任意一项所述护肝解酒藏药组方的制备方法,其特征在于,包括以下步骤:
(1)按照以下质量份称取藏药组分:藏红花1~3份、藏木香4~6份、干姜9~12份、芫荽9~12份、牛黄10~15份,豆蔻3~5份,胡椒0.2~0.6份,红景天0.8~1.2份,寒水石20~30份,灵芝40~60份;
(2)取藏红花进行纳米粉碎至粒径小于100nm,灭菌,备用;
(3)取藏木香,加水微波提取两次,每次40min,料液比1:10,合并提取液,旋转蒸发浓缩为浸膏状;
(4)取干姜,加水微波提取两次,每次30min,料液比1:10,合并提取液,旋转蒸发浓缩为浸膏状;
(5)取芫荽进行纳米粉碎至粒径小于100nm,灭菌,备用;
(6)取牛黄进行纳米粉碎至粒径小于100nm,灭菌,备用;
(7)取豆蔻加水微波提取三次,每次50min,料液比1:12,合并提取液,旋转蒸发浓缩为浸膏状;
(8)取胡椒进行纳米粉碎至粒径小于100nm,灭菌,备用;
(9)取红景天进行纳米粉碎至粒径小于100nm,灭菌,备用;
(10)取寒水石加水微波提取三次,每次50min,料液比1:12,合并提取液,旋转蒸发至1/3体积,加三倍无水乙醇进行醇沉,抽滤除去沉淀,再旋转浓缩为浸膏状;
(11)取灵芝加水微波提取两次,每次30min,料液比1:10,合并提取液,旋转蒸发浓缩为浸膏状。
5.一种利用权利要求4所述护肝解酒藏药组方制备方法制备护肝解酒藏药组方咀嚼片的方法,其特征在于,还包括以下步骤:取蔗糖、甘露醇进行纳米粉碎至粒径小于100nm,备用;取步骤(3)、(4)、(7)、(10)、(11)的浸膏,加入步骤(2)、(5)、(6)、(8)、(9)的粉末以及蔗糖和甘露醇粉末,混合制粒,干燥,整粒,再加入2%的硬脂酸镁,混匀整粒,压片,即得成品。
6.根据权利要求5所述制备护肝解酒藏药组方咀嚼片的方法,其特征在于,所述蔗糖和甘露醇粉末的加入量占总重量的百分比为20%~40%。
7.根据权利要求6所述制备护肝解酒藏药组方咀嚼片的方法,其特征在于,所述蔗糖和甘露醇粉末的重量比为3:1~1:1。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111351160.7A CN114042143A (zh) | 2021-11-15 | 2021-11-15 | 一种护肝解酒藏药组方的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111351160.7A CN114042143A (zh) | 2021-11-15 | 2021-11-15 | 一种护肝解酒藏药组方的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114042143A true CN114042143A (zh) | 2022-02-15 |
Family
ID=80209296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111351160.7A Pending CN114042143A (zh) | 2021-11-15 | 2021-11-15 | 一种护肝解酒藏药组方的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114042143A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103169930A (zh) * | 2011-12-20 | 2013-06-26 | 刘桂元 | 一种解酒剂及其制备方法 |
CN109330973A (zh) * | 2018-12-14 | 2019-02-15 | 平措热旦 | 一种植物萃取水洗面膜及其制备方法 |
CN111714539A (zh) * | 2019-03-22 | 2020-09-29 | 江苏康缘药业股份有限公司 | 一种护肝的组合物及其制备方法和应用 |
-
2021
- 2021-11-15 CN CN202111351160.7A patent/CN114042143A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103169930A (zh) * | 2011-12-20 | 2013-06-26 | 刘桂元 | 一种解酒剂及其制备方法 |
CN109330973A (zh) * | 2018-12-14 | 2019-02-15 | 平措热旦 | 一种植物萃取水洗面膜及其制备方法 |
CN111714539A (zh) * | 2019-03-22 | 2020-09-29 | 江苏康缘药业股份有限公司 | 一种护肝的组合物及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
陈秀锦,等: "灵芝红景天复方胶囊对化学性肝损伤辅助保护作用的研究", 《海峡预防医学杂志》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5340302B2 (ja) | キグシを含む加味雙和湯を有効成分として含有する二日酔い解消用組成物 | |
CN102640864B (zh) | 提高鸡免疫力预防腹泻的中草药饲料添加剂及其使用方法 | |
CN102885856B (zh) | 用美洲大蠊提取物生产治疗乙型肝炎药物的生产方法 | |
CN102716223B (zh) | 一种治疗上呼吸道感染的中药组合物及其制备方法 | |
TW201916876A (zh) | 一種具有增強免疫力功能的粉劑及其製備方法 | |
CN106309506A (zh) | 一种具有调经功能的益生菌组合物及其应用 | |
CN103371367B (zh) | 艾滋病营养疗法的一种食品 | |
CN106721005A (zh) | 罗非鱼用预防链球菌病饲料添加剂 | |
CN114042143A (zh) | 一种护肝解酒藏药组方的制备方法 | |
CN102078600B (zh) | 抗癌复方灵芝组合物、其用途和包含其的药物组合物 | |
CN102697959A (zh) | 一种预防和治疗猪呼吸道病综合症的中兽药 | |
CN111603522A (zh) | 一种具有降血糖作用的辣椒叶组合物及其制备方法和应用 | |
CN111700974A (zh) | 一种石斛滋阴降糖丸及其制备方法 | |
CN1736261A (zh) | 解酒保肝保健食品 | |
CN102793869A (zh) | 一种用于防治猪病毒性疾病的中药组合物及其制备方法 | |
CN117085086B (zh) | 一种补气血发酵物及其制备工艺、应用 | |
CN110025643B (zh) | 一种抗癌活性复方物及其制备方法与应用 | |
CN112023018B (zh) | 一种用于防治家畜腹泻的中药组合物及其制备方法与应用 | |
CN108432968A (zh) | 一种用于改善獭兔毛皮品质的饲料添加剂及其制备方法 | |
CN108096570A (zh) | 具有排毒减肥功能的虫草蛋白肽片 | |
CN107007752B (zh) | 一种提高缺氧耐受力的中药组合物 | |
CN105596411A (zh) | 一种治疗支气管炎的板蓝根颗粒及其制备方法和应用 | |
CN115777847A (zh) | 一种增强体质的家禽饲料添加剂、制剂及保健饲料 | |
CN113491726A (zh) | 一种防治肺炎提高机体抗病能力的中药组合物及其应用 | |
CN118286338A (zh) | 一种中药组合物、制备方法及应用和一种营养药膳及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220215 |